Resources
23 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 3/29/2024 (updated 4/4/2024)
This session offered a review of the programmatic work of the Foundation for Opioid Response Efforts (FORE), discussed different types of funding opportunities, and then used FORE’s application process as an example of applying for and receiving funding from private foundations.
Posted 2/9/2024 (updated 3/28/2024)
The Center for Financing Reform and Innovation (CFRI) is a SAMHSA contract that seeks to understand financing mechanisms of behavioral health care to identify opportunities, innovations, and challenges to service delivery and access. Learn about behavioral health financing mechanisms, options, and innovations through CFRI reports and webinars using the CFRI website.
Posted 8/18/2023 (updated 3/26/2024)
The National Institute on Drug Abuse (NIDA) Center for the Clinical Trials Network (CCTN) held an event where health care professionals and federal partners discussed xylazine-related testing, treatment, and wound care. As the White House has deemed fentanyl adulterated with xylazine an emerging threat, it is important to identify and adapt to the rapidly changing practices of patient care.
Posted 3/14/2023 (updated 3/27/2024)
Xylazine is a non-opioid that is approved for animals, and not FDA-approved for humans. New York State's Department of Health provides information on what it is, sources and trends, effects, why people use it, why clinicians should be concerned, and other information on Xylazine. Information about Xylazine is important to understand now that it has been showing up in illicit drug supply.
Posted 7/12/2022 (updated 3/27/2024)
Syringe services programs (SSP) are harm reduction programs that provide a wide range of services including, but not typically limited to, the provision of new, unused hypodermic needles and syringes and other injection drug use supplies, such as cookers, tourniquets, alcohol wipes, and sharps waste disposal containers, to people who inject drugs. In this summary, readers will find information with respect to SSPs for each state, including citations to applicable statutes and/or regulations, whether the state allows SSPs by statute, whether there are any municipal or county ordinances or regulations in place within the state, program components, miscellaneous provisions, and information on any pending legislation.
Posted 6/7/2022 (updated 3/27/2024)
This session provided information on program updates and the Year 2 Sustainability template due September 2022.
Posted 6/7/2022 (updated 3/27/2024)
This session began with a discussion of the timeline, PIMS, sustainability plan, and no cost extensions with the Implementation I cohort. The Implementation II cohort joined the discussion and information was provided on sustaining change in communities.
Posted 3/21/2022 (updated 3/27/2024)
People who inject drugs (PWID) are likely to experience wounds and infection related to their injection drug use. Common wounds and infections experienced by PWID include blood poisoning (septicemia), infection of the heart lining (endocarditis), tetanus, hepatitis, bruising, collapsed veins, abscesses and blood clots. Preventing and caring for wounds in PWID requires special consideration of the conditions surrounding drug use.
Posted 11/11/2021 (updated 4/3/2024)
This session provided participants with realistic and achievable steps to help consortiums leverage their RCORP-Planning efforts to achieve long-lasting sustainable impact. Participants heard from two RCORP-Planning III sites that are successfully navigating and securing sustainability for their communities using different approaches.
Posted 9/29/2021 (updated 4/3/2024)
In this re-welcome session, HRSA Project Officers shared reminders and updates about grant deliverables, the Evaluation Team will gave updates, and Technical Expert Leads discussed new and ongoing technical assistance available to Implementation I, Implementation II and MAT-Expansion grantees.